Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 2467870, 6 pages
https://doi.org/10.1155/2017/2467870
Research Article

Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis

1Department of Neurology, PLA General Hospital, No. 28, Fuxing Road, Beijing 100853, China
2Department of Neurology, PLA General Hospital, Hainan Branch, Haitang Bay, Sanya, Hainan 57200, China

Correspondence should be addressed to Chenglin Tian; moc.nuyila@917nilgnehcnait

Received 1 November 2016; Revised 2 January 2017; Accepted 1 February 2017; Published 19 February 2017

Academic Editor: Paola Gazzaniga

Copyright © 2017 Zhen Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. Glass, M. Melamed, N. L. Chernik, and J. B. Posner, “Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology,” Neurology, vol. 29, no. 10, pp. 1369–1375, 1979. View at Publisher · View at Google Scholar · View at Scopus
  2. B.-S. Yap, H.-Y. Yap, G. Blumenschein, H. A. Fritsche, and G. P. Bodey, “CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer,” JAMA: The Journal of the American Medical Association, vol. 244, no. 14, pp. 1601–1603, 1980. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Twijnstra, A. P. van Zanten, W. J. Nooyen, and B. W. O. de Visser, “Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 49, no. 11, pp. 1246–1250, 1986. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Nakagawa, S. Kubo, A. Murasawa et al., “Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors,” Journal of Neuro-Oncology, vol. 12, no. 2, pp. 111–120, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Corsini, G. Bernardi, P. Gaviani et al., “Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 7, pp. 874–879, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Kang, K. S. Kim, Y. S. Ha et al., “Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis,” Journal of Clinical Neurology, vol. 6, no. 1, pp. 33–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Wang, Y. Piao, X. Zhang, W. Li, and X. Hao, “The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer,” Cancer Biomarkers, vol. 13, no. 2, pp. 123–130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Moldrich, P. Lange, and H. Strik, “Carcinoembryonic antigen in the CSF of cancer patients—the value of intrathecal synthesis and correlation with IgA-diffusion dynamics,” Acta Neurologica Belgica, vol. 110, no. 4, pp. 314–320, 2010. View at Google Scholar · View at Scopus
  9. A.-S. Gauchez, E. Pez, J. Boutonnat et al., “Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: validation of CA 15-3 measurement in cerebrospinal fluid,” Annales de Biologie Clinique, vol. 65, no. 6, pp. 653–658, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. G. Mammoser and M. D. Groves, “Biology and therapy of neoplastic meningitis,” Current Oncology Reports, vol. 12, no. 1, pp. 41–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. L. Clarke, “Leptomeningeal metastasis from systemic cancer,” CONTINUUM Lifelong Learning in Neurology, vol. 18, no. 2, pp. 328–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Leal, J. E. Chang, M. Mehta, and H. I. Robins, “Leptomeningeal metastasis: challenges in diagnosis and treatment,” Current Cancer Therapy Reviews, vol. 7, no. 4, pp. 319–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. Martins, C. R. A. S. D. Azevedo, L. T. D. Chinen, M. R. S. Cruz, M. A. Peterlevitz, and D. L. Gimenes, “Meningeal carcinomatosis in solid tumors,” Arquivos de Neuro-Psiquiatria, vol. 69, no. 6, pp. 973–980, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Gleissner and M. C. Chamberlain, “Neoplastic meningitis,” Lancet Neurology, vol. 5, no. 5, pp. 443–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. R. H. Xu, C. Z. Liao, Y. Luo et al., “Optimal cut-off values for CYFRA 21-1 expression in NSCLC patients depend on the presence of benign pulmonary diseases,” Clinica Chimica Acta, vol. 440, pp. 188–192, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Reiber, “Dynamics of brain-derived proteins in cerebrospinal fluid,” Clinica Chimica Acta, vol. 310, no. 2, pp. 173–186, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. I. J. Fidler, “The role of the organ microenvironment in brain metastasis,” Seminars in Cancer Biology, vol. 21, no. 2, pp. 107–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. D. Beasley and S. A. Toms, “The molecular pathobiology of metastasis to the brain: a review,” Neurosurgery Clinics of North America, vol. 22, no. 1, pp. 7–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Grewal, H. Zhou, R. Factor, and S. Kesari, “Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer,” Journal of Clinical Oncology, vol. 28, no. 13, pp. e200–e202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S.-J. Ding, Y. Li, Y.-X. Tan et al., “From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis,” Molecular and Cellular Proteomics, vol. 3, no. 1, pp. 73–81, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P.-Y. Zhuang, J.-B. Zhang, X.-D. Zhu et al., “Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor,” Cancer, vol. 112, no. 12, pp. 2740–2748, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. C. J. R. Stewart, M. L. Crook, J. Lacey, and K. Louwen, “Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium,” International Journal of Gynecological Pathology, vol. 30, no. 5, pp. 484–491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Cristofori, G. Aimo, G. Mengozzi, A. Oliaro, F. Revello, and M. Rapellino, “Tumor markers kinetic in malignant lung neoplasms,” Journal of Cardiovascular Surgery, vol. 40, no. 2, pp. 299–305, 1999. View at Google Scholar · View at Scopus